Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BIODESIX INC reported revenue of $88M, up 24.1% year over year. Operating margin was -31.5% and net margin -39.8%, on a free-cash-flow margin of -26.6% with capital expenditure at 0.3% of revenue. Every figure is computed directly from BDSX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $88M | -31.5% | -39.8% |
| FY2024 | $71M | -48.4% | -60.2% |
| FY2023 | $49M | -84.2% | -106.2% |
| FY2022 | $38M | -132.4% | -171.3% |
| FY2021 | $55M | -75.1% | -79.2% |
How does BDSX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.